216.73.216.231===--UPDATE `0-usmeigara` SET site='',name='',jigyoyoyaku='',sijyo='',gyosyu='',honten='',industry='',sector='',haishi='',keyword='' where code = 'aclx'---select * from `0-usmeigara` WHERE code='aclx'
aaアーセルクス

aclx
銘柄登録／業種登録　関連銘柄専用コメ／リスト／日本株
・

url
name
code
業種
htmldesc　分割：<split>
がん患者および他の治癒不能な疾患患者向けに様々な免疫療法の開発に取り組んでいます。主力のddCAR製品候補は、r/r多発性骨髄腫（MM）患者の治療のためのフェーズ2臨床試験中のCART-ddBCMAです。また、r/r MMを治療するためのARC-T細胞とBCMAを標的とするSparX蛋白質から成るACLX-001など、AMLおよびMDSの治療薬も開発中
keyword
sijyo
honten
industry
sector
haishi

事業内容も含めて検索

日本語に翻訳して１５０文字程度で要約を。語尾は「している」等の常体で
「Arcellx, Inc., a clinical-stage biotechnology company, engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company's lead ddCAR product candidate is CART-ddBCMA, which is in phase 2 clinical trial for the treatment of patients with relapsed or refractory (r/r) multiple myeloma (MM). It is also developing ACLX-001, an immunotherapeutic combination composed of ARC-T cells and bi-valent SparX proteins targeting BCMA to treat r/r MM; ACLX-002 and ACLX-003 for treating r/r acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS); and product candidates for solid tumor programs. It has strategic alliance with Kite Pharma, Inc. to co-develop and co-commercialize CART-ddBCMA. The company was formerly known as Encarta Therapeutics, Inc. and changed its name to Arcellx, Inc. in January 2016. Arcellx, Inc. was incorporated in 2014 and is headquartered in Gaithersburg, Maryland.」